BUY CDSL. Strong Operating Performance; Maintain BUY. Target Price: Rs435. Institutional Equity Research. 2QFY18 Result Update October 31, 2017

Similar documents
CMP* (Rs) 360 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 38 Free Float (%) 76 Shares O/S (mn) 104.5

CMP* (Rs) 1,464 Upside/ (Downside) (%) 10. Market Cap. (Rs bn) 91 Free Float (%) 55 Shares O/S (mn) 62

CMP* (Rs) 242 Upside/ (Downside) (%) 2. Market Cap. (Rs bn) 157 Free Float (%) 65.6 Shares O/S (mn) 630

CMP (Rs) 775 Upside/ (Downside) (%) (1.4) Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7

CMP* (Rs) 840 Upside/ (Downside) (%) (2.4) Bloomberg Ticker Market Cap. (Rs bn) 379 Free Float (%) 53 Shares O/S (mn) 451.6

CMP* (Rs) 208 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) Free Float (%) 65.6 Shares O/S (mn) 630

CMP* (Rs) 166 Upside/ (Downside) (%) 28 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,361 Free Float (%) 37.7 Shares O/S (mn) 8,245

CMP* (Rs) 336 Upside/ (Downside) (%) 21 Bloomberg Ticker. MOIL IN Market Cap. (Rs bn) 45 Free Float (%) 24 Shares O/S (mn) 133

CMP* (Rs) 161 Upside/ (Downside) (%) 19 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,329 Free Float (%) 30.3 Shares O/S (mn) 8,245

CMP* (Rs) 172 Upside/ (Downside) (%) 11.6 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,414 Free Float (%) 30.3 Shares O/S (mn) 8,245

CMP* (Rs) 263 Upside/ (Downside) (%) 7.3. Market Cap. (Rs bn) 635 Free Float (%) 59 Shares O/S (mn) 2,417

CMP* (Rs) 203 Upside/ (Downside) (%) 23. Market Cap. (Rs bn) 116 Free Float (%) 61 Shares O/S (mn) 572

CMP* (Rs) 1,458 Upside/ (Downside) (%) 10 Bloomberg Ticker. ABB IN Market Cap. (Rs bn) 309 Free Float (%) 25 Shares O/S (mn) 212

CMP* (Rs) 417 Upside/ (Downside) (%) 46 Bloomberg Ticker. SUNP IN Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399

CMP* (Rs) 346 Upside/ (Downside) (%) 17. Market Cap. (Rs bn) 23 Free Float (%) 42.0 Shares O/S (mn) 67

CMP* (Rs) 1,033 Upside/ (Downside) (%) (0.3) Bloomberg Ticker Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452

CMP* (Rs) 289 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) 30 Free Float (%) 69 Shares O/S (mn) 105

Nestlé India Outlook Hazy; Valuations Prohibitive

CMP* (Rs) 205 Upside/ (Downside) (%) 12 Bloomberg Ticker. NACO IN Market Cap. (Rs bn) 29 Free Float (%) 27 Shares O/S (mn) 143

BUY NCC. An Ordinary Quarterly Performance; Maintain BUY. Target Price: Rs98. Institutional Equity Research. 4QFY17 Result Update May 24, 2017

HOLD. Nestle. Good Performance Irrespective of GST Pangs. Target Price: Rs6,624. Institutional Equity Research. 2QCY17 Result Update July 27,2017

Sonata Software HOLD. Unimpressive Show; IITS Revenue Disappoints. Institutional Equity Research. February 06, Target Price Rs190.

Titan Company BUY. Back to Value Zone Validate Rating Upgrade. Institutional Equity Research. November 05, Target Price Rs428.

BUY NTPC. Higher Regulated Equity to Aid Profitability; Maintain BUY. Target Price: Rs192. Institutional Equity Research

HOLD ACC. Strong Performance on Better Volume and Firm Realizations. Target Price: Rs1,640. Institutional Equity Research

CMP (Rs) 326 Upside/ (Downside) (%) 24. Market Cap. (Rs bn) 21.7 Free Float (%) 42.0 Shares O/S (mn) 67

CMP (Rs) 249 Upside/ (Downside) (%) Market Cap. (Rs bn) 25.5 Free Float (%) 29.7 Shares O/S (mn) 102.3

CMP* (Rs) 237 Upside/ (Downside) (%) 29 Bloomberg Ticker. APTY IN Market Cap. (Rs bn) 136 Free Float (%) 55.9 Shares O/S (mn) 509

BUY. DCB Bank. Improving Capital Consumption to Aid Returns; Maintain BUY. Target Price: Rs202. Institutional Equity Research

CMP* (Rs) 198 Upside/ (Downside) (%) 12. Market Cap. (Rs bn) 61 Free Float (%) 84 Shares O/S (mn) 308

CMP* (Rs) 189 Upside/ (Downside) (%) (1) Bloomberg Ticker PNB IN Market Cap. (Rs bn) 402 Free Float (%) 38 Shares O/S (mn) 2,128

KNR Constructions Robust Performance on Execution Ramp-up

CMP* (Rs) 145 Upside/ (Downside) (%) 32 Bloomberg Ticker BOB IN Market Cap. (Rs bn) 384 Free Float (%) 36 Shares O/S (mn) 2,646

CMP (Rs) 133 Upside/ (Downside) (%) 35 Bloomberg Ticker. ICEM IN Market Cap. (Rs bn) 41 Free Float (%) 71.6 Shares O/S (mn) 308.1

CMP* (Rs) 1,424 Upside/ (Downside) (%) 19 Bloomberg Ticker Market Cap. (Rs bn) 268 Free Float (%) 46 Shares O/S (mn) 188

CMP (Rs) 166 Upside/ (Downside) (%) (1) Bloomberg Ticker Market Cap. (Rs bn) 125 Free Float (%) 37 Shares O/S (mn) 726

CMP (Rs) 702 Upside/ (Downside) (%) 42 Bloomberg Ticker. JKCE IN Market Cap. (Rs bn) 54 Free Float (%) 42 Shares O/S (mn) 77.3

Near-term pressure, but long-term outlook positive

Aurobindo Pharma. Institutional Equity Research. Sector - Pharmaceuticals. RSec TradEdge India. March 02, 2017

Sonata Software BUY. Laying the Platform for Growth. Institutional Equity Research. December 01, Target Price Rs185.

Jubilant FoodWorks. Institutional Equity Research. Sector - FMCG. RSec TradEdge India. January 17, 2017

Central Depository Services

Central Depository Services

Marico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015

Central Depository Services

Key estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,

CMP* (Rs) 301 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 19.6 Free Float (%) 26 Shares O/S (mn) 65

Crompton Greaves Consumer Electricals

Healty cigarette-driven growth

GMM Pfaudler Limited BUY. Performance Update CMP. `945 Target Price ` QFY2019 Result Update Industrial Machinery. Investment Period 12 Months

BLS International Services

Parag Milk Foods BUY. Performance Update CMP. `256 Target Price `330. 2QFY2019 Result Update Dairy Products. Investment Period 12 Months

Amber Enterprises India Ltd

Multi Commodity Exchange

Crompton Greaves Consumer Electricals

Hindustan Media Ventures

KEC International. Recovering from a weak phase. Institutional Equity Research. Order inflow traction remains intact

Strides Arcolab. Inline 4Q, recent acquisitions to deepen asset growth. Institutional Equity Research. Strides Arcolab. Pharmaceuticals India

Parag Milk Foods BUY. Performance Update CMP. `324 Target Price `410. 1QFY2019 Result Update Dairy Products. Investment Period 12 Months

ITC ACCUMULATE. Performance Highlights CMP. `257 Target Price `284. 3QFY2017 Result Update FMCG. Investment Period 12 Months

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

Jubilant FoodWorks BUY RESULTS REVIEW 1QFY18 18 JULY Highlights of the quarter

Power Mech Projects. Institutional Equities. 2QFY19 Result Update BUY. Strong Order Book Drives Robust Execution

Adani Ports & SEZ Rating: Target price: EPS:

Jubilant FoodWorks NEUTRAL RESULTS REVIEW 4QFY17 30 MAY Highlights of the quarter

Bata India BUY. Performance Update. CMP Target Price `842. 1QFY2019 Result Update Footwear. Historical share price chart.

Cyient. Good show, priced in NEUTRAL RESULTS REVIEW 4QFY17 21 APRIL Highlights of the quarter

Consolidated Sales (Cr) Growth EBITDA (Cr) Margin PAT Margin EPS (Rs) P/E RoE

Mahindra & Mahindra Ltd.

Music Broadcast BUY. Performance Update. CMP Target Price `293 `475. 3QFY2019 Result Update Media. Stock Info Sector Market Cap (Rs cr) Media

Music Broadcast BUY. Performance Update. CMP Target Price `329 `475. 2QFY2019 Result Update Media. Historical share price chart.

Blue Star Ltd BUY. Performance Update. CMP Target Price `703 `867. 1QFY2019 Result Update Cons. Durable. 3-year price chart.

Mahindra & Mahindra Ltd.

Visaka Industries Ltd

Gillette India. Institutional Equities. 1QFY18 Result Update

Maruti Suzuki India BUY. Performance Update. CMP `9,315 Target Price `10,820. 1QFY2019 Result Update Automobile. Historical share price chart

Garware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months

Bata India BUY. Performance Update. CMP `1,008 Target Price `1,243. 2QFY2019 Result Update Footwear. Historical share price chart.

Rallis India NEUTRAL. Performance Highlights CMP. `237 Target Price - 1QFY2018 Result Update Agrichemical. Investment Period - 3-year price chart

HCC BUY. Infrastructure April 10, QIP step in the right direction EVENT UPDATE. India Research. Bloomberg: HCC IN Reuters: HCNS.

Initiating Coverage. Uflex Ltd.

TV Today Network BUY. Performance Update CMP. `323 Target Price `498. 3QFY2019 Result Update Media. Investment Period 12 Months

Balkrishna Industries

Colgate-Palmolive (India)

Quick take. Ruchira Papers Ltd. BUY. Creating value through paper. Target Price. Investment Period 12 Months. 3 year daily price chart.

Ahluwalia Contracts. Cautious optimism BUY RESULTS REVIEW 4QFY17 31 MAY Highlights of the quarter

Fineotex Chemical Ltd

MCX Ltd. Rating: Target price: EPS: Tepid volume growth continues. Target. Rating CMP. Rs. 1,080 SELL. Rs. 1,176

Rallis India NEUTRAL. Performance Highlights CMP. `215 Target Price - 3QFY2017 Result Update Agrichemical. Investment Period - 3-year price chart

Intellect Design Arena

TTK Prestige Ltd. Result Highlights. Revenue growth of 41% YoY, shows no slowdown yet. OPM at ~15.8%; in line with our estimate

Vadodara II PPA yet to be signed; TP revised upward to Rs126 on FY19x

Maruti Suzuki India BUY. Performance Update. CMP `6,705 Target Price `8,552. 2QFY2019 Result Update Automobile. Historical share price chart

Cummins India Ltd Bloomberg Code: KKC IN

Religare Investment Call

KEC International Ltd.

Dr Reddy s Laboratories

Inox Wind BUY. Performance Highlights. CMP Target Price `390 `505. 2QFY2016 Result Update Capital Goods. 3 year price chart

Institutional Equities

Kalpataru Power. Rating: Target price: EPS: Rating CMP. Target BUY. Rs Rs.256

Transcription:

2QFY18 Result Update October 31, 2017 CMP* (Rs) 371 Market Cap. (Rs bn) 39 Free Float (%) 76 Shares O/S (mn) 104.5 Strong Operating Performance; Maintain Central Depository Services () has reported a strong set of operational numbers in 2QFY18. Its revenue rose by a healthy 22.4% YoY to Rs472mn led by 18.2% YoY growth in Depository segment. On the other hand, Data Processing revenue rose by a strong 35.2% YoY. The strong revenue growth was aided by good health of capital markets with the key indices hitting all-time highs and strong new MF account openings. Key growth drivers in terms of businesses were Transaction charges (+26% YoY), IPO/Corporate Action charges (+68% YoY) and KYC/Online Data Charges (+41% YoY). Owing to operating leverage and cost control, s EBITDA margin powered ahead by 221bps YoY to 63.5%, and by 26.8% YoY in absolute terms to Rs300mn. However, owing to lower other income (-17.6% YoY) and a higher eective tax rate, reported PAT rose at a slower pace than EBITDA, by 10.5% YoY to Rs267mn. Revenue Growth, Margins Impress s revenue grew by an impressive 22.4% YoY, aided by all-round growth in both Depository segment and the Data Processing segment. Depository revenue rose by a healthy 18.2% YoY to Rs360mn, aided by healthy capital markets and strong growth in depository accounts due to increasing investor interest. On the other hand, Data Processing revenue rose by a robust 35.2% YoY to Rs102mn aided by healthy state of capital markets and strong downstream revenue related to KYC services led by new demat account openings. On a sequential basis, Depository revenue rose by a robust 21.1%, while Data Processing revenue rose by 4.3%. On EBIT margin front, Depository segment saw a strong 362bps YoY increase, with EBIT in absolute terms surging by 26.4% YoY to Rs202mn. On the other hand, the Data Processing segment recorded a 569bps YoY dip in EBIT margin, even as EBIT in absolute terms rose by 25.8% YoY to Rs77mn. Sequentially, Depository segment EBIT margin surged by 1,266bps (EBIT up 56.4% QoQ), while Data Processing EBIT margin declined by 635bps (EBIT down 3.6% QoQ). Share price (%) 1 mth 3 mth 12 mth Absolute performance 8.4 9.3 N.A. Relative to Nifty 2.8 6.7 N.A. Shareholding Pattern (%) Jul 17 Sep'17 Promoter 24.0 24.0 Public 76.0 76.0 1 Year Stock Price Performance 500 450 400 350 300 250 200 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Note: * CMP as on October 31, 2017 Outlook & Valuation In light of highly predictable revenue model, good health of capital markets, market leadership based on incremental BO accounts, high profitability and cash flow, and newer business initiatives, we believe the stock is a very good long-term investment. At the CMP, the stock trades at a PE of 31.8x FY19E EPS. Trimming down our EPS estimates by 4%, we maintain our recommendation on the stock with a revised Target Price of Rs435 (from Rs450 earlier). Key Financials (Rs mn) FY16 FY17 FY18E FY19E Net Sales 1,229 1,460 1,836 2,149 EBITDA 639 794 1,074 1,274 RPAT 910 858 1,049 1,222 Diluted EPS (Rs) 8.7 8.2 10.0 11.7 P/E (x) 42.7 45.2 37.0 31.8 EV / EBITDA (x) 56.2 45.4 32.9 27.2 RoE (%) 20.3 16.9 18.5 19.1 Research Analyst: Harit Shah Contact: 022 33201276 Email: harit.shah@relianceada.com 1

Conference Call Key Takeaways continues to remain the leader in demat segment in terms of incremental market share of 62% and also it remains the market leader in e-voting business. The company has inaugurated Commodity Repository (CCR), where warehouse receipts can be safely stored in demat form, against which financing can be made. s promoter company, Bombay Stock Exchange (BSE) along with Multi Commodity Exchange (MCX) have expressed interest in taking a stake in CCR, and the company will conduct a postal ballot for obtaining shareholders approval for this. The company earned lower other income owing to Rs650-700mn being invested towards property, which reduced investible surplus, apart from lower debt yields due to falling interest rates. s National Academic Depository (NAD) is undergoing decent traction with >160 universities and academic institutions having signed up. Risks to the View Emergence of new technologies like Blockchain, which are being tested by SEBI, could potentially eat into some parts of s business. Increasing competition with entry of a possible 3rd player into the depository space and fierce price competition from key competitor, NSDL. Any eventual downturn in equity markets could adversely impact growth in BO accounts and lead to slower growth or even de-growth in transaction revenue. Appointment of CERSAI as central KYC registration agency could impact Ventures KYC business. Generic risks typically faced by electronic online systems such as cyber-attacks. Exhibit 1: Quarterly Performance (Consolidated) Particulars (Rs mn) 2QFY18 2QFY17 YoY (%) 1QFY18 QoQ (%) Net Revenues 472 386 22.4 405 16.5 Employee Expenses 66 54 23.1 70 (6.1) Other Operating Expenses 106 96 11.1 106 0.8 EBITDA 300 237 26.8 230 30.7 Depreciation 14 9 52.8 10 33.6 EBIT 286 227 25.8 219 30.5 Other Income 91 110 (17.6) 98 (7.2) PBT 377 337 11.6 317 18.9 Minority Interest and associate profits 1 4 (64.9) 2 (24.5) Tax 108 92 17.5 62 74.0 APAT 267 242 10.5 253 5.6 E/o (adj for tax) 0 0-0 - RPAT 267 242 10.5 253 5.6 2

Exhibit 2: Margin Break Up Particulars (%) 2QFY18 2QFY17 YoY (bps) 1QFY18 QoQ (bps) Employee Expenses % Net Revenues 14.0 13.9 9 17.4 (337) Other Expenses % Net Revenues 22.5 24.8 (230) 26.0 (351) EBITDA Margin (%) 63.5 61.3 221 56.6 688 EBIT Margin (%) 60.5 58.9 162 54.0 650 Tax Rate (%) 28.7 27.3 145 19.6 910 APAT Margin (%) 56.6 62.6 (608) 62.4 (584) Exhibit 3: Earlier, revised estimates Particulars Earlier estimates Revised estimates % change Earlier estimates Revised estimates % change FY18E FY19E Revenue (Rs mn) 1,868 1,836 (1.7) 2,187 2,149 (1.7) EBITDA (Rs mn) 1,037 1,074 3.6 1,236 1,274 3.1 EBITDA margin (%) 55.5 58.5 300 bps 56.5 59.3 275 bps EPS (Rs) 10.5 10.0 (4.1) 12.2 11.7 (3.9) Source: RSec Research Exhibit 4: Segment-wise contribution (% of gross revenue) 4QFY16 1QFY17 2QFY17 3QFY17 4QFY17 1QFY18 2QFY18 Depository Activity 75.2 76.1 78.5 79.7 76.9 73.0 75.9 Data Processing Services 22.5 21.7 19.4 18.4 21.7 23.9 21.4 Others 2.3 2.1 2.1 1.8 1.4 3.1 2.7 Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 Exhibit 5: Segment-wise growth (YoY, %) 4QFY16 1QFY17 2QFY17 3QFY17 4QFY17 1QFY18 2QFY18 Depository Activity N.A. 42.0 42.0 (2.3) 19.0 23.1 18.2 Data Processing Services N.A. 9.8 10.2 21.4 12.1 41.4 35.2 Others N.A. 11.5 3.5 11.7 (26.5) 87.1 56.0 Total N.A. 33.0 32.8 1.6 15.8 28.6 22.4 Exhibit 6: Segment-wise EBIT margins (% of revenue) 4QFY16 1QFY17 2QFY17 3QFY17 4QFY17 1QFY18 2QFY18 Depository Activity 32.4 41.2 52.6 43.9 39.4 43.5 56.2 Data Processing Services 77.6 79.7 81.9 78.5 78.2 82.6 76.2 Others 73.8 63.0 69.3 70.5 (29.9) 72.1 47.8 Total 43.5 50.3 58.9 50.8 47.1 54.0 60.5 Exhibit 7: Segment-wise EBIT contribution (% of gross EBIT) 4QFY16 1QFY17 2QFY17 3QFY17 4QFY17 1QFY18 2QFY18 Depository Activity 56.0 62.7 70.5 69.0 64.7 59.1 70.8 Data Processing Services 40.2 34.6 27.1 28.5 36.2 36.7 27.1 Others 3.8 2.7 2.5 2.5 (0.9) 4.2 2.1 Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 3

Profit and Loss Statement Y/E March (Rs mn) FY16 FY17 FY18E FY19E Net Sales 1,229 1,460 1,836 2,149 Growth (%) 16.7 18.8 25.8 17.1 Employee Expenses 215 249 285 328 Other Expenses 374 417 477 548 EBITDA 639 794 1,074 1,274 EBITDA (%) 52.0 54.4 58.5 59.3 EBITDA Growth (%) 41.5 24.3 35.2 18.6 Depreciation & Amortisation 42 37 47 58 EBIT 597 757 1,027 1,216 EBIT (%) 48.6 51.9 56.0 56.6 EBIT Growth (%) 53.4 26.8 35.7 18.4 Other Income 385 408 420 480 PBT 982 1,166 1,448 1,696 PBT Margin (%) 79.9 79.8 78.9 78.9 PBT Growth (%) 24.1 18.7 24.2 17.2 Tax (incl deferred) 402 300 391 467 Minority Interest 1 8 8 8 Extraordinary Items 331 0 0 0 APAT 910 858 1,049 1,222 PAT Margin (%) 74.1 58.8 57.1 56.8 PAT Growth (%) 57.8 (5.7) 22.3 16.5 EPS 8.7 8.2 10.0 11.7 Balance Sheet Y/E March (Rs mn) FY16 FY17 FY18E FY19E SOURCES OF FUNDS Share Capital - Equity 1,045 1,045 1,045 1,045 Reserves 3,748 4,288 4,959 5,741 Total Shareholders' Funds 4,793 5,333 6,004 6,786 Minority Interest 147 155 163 171 Long Term Provisions & Others 5 6 6 6 Deferred Tax Liabilities (Net) 29 7 7 7 Creditors 73 90 94 108 Other Current Liabilities & Provns 482 481 492 505 Total Current Liabilities 556 571 586 613 TOTAL SOURCES OF FUNDS 5,530 6,072 6,767 7,584 APPLICATION OF FUNDS Net Block 30 47 55 51 Goodwill & Other Intangible Assets 7 8 8 8 Investments 2,105 2,729 2,729 2,729 Deferred Tax Assets - 23 23 23 LT Loans & Advances, Others 297 228 228 228 Total Non Current Assets 2,439 3,035 3,043 3,039 Cash & Bank 404 483 1,126 1,899 Liquid Investments 2,470 2,300 2,300 2,300 Debtors 130 133 176 224 Loans & Advances and Others 88 122 122 122 Total Current Assets 3,091 3,038 3,724 4,545 TOTAL APPLICATION OF FUNDS 5,530 6,072 6,767 7,584 4

Cash Flow Statement Y/E March (Rs mn) FY16* FY17 FY18E FY19E PAT 248 858 1,094 1,272 Non-operating & EO items 0 0 (63) (73) Depreciation 42 37 47 58 Working Capital Change (360) (101) (28) (21) Cash Flow from Operations (a) (70) 794 1,049 1,235 Capex (18) (53) (55) (54) Investments 21 235 0 0 Cash Flow from Investing (b) 3 182 (55) (54) Debt Issuance/(Repaid) 0 0 0 0 Share capital Issuance 0 0 0 0 Dividend (277) (314) (315) (367) Cash Flow from Financing (c) (277) (314) (315) (367) NET CASH FLOW (a+b+c) (344) 662 679 815 EO items, others 365 (689) (600) (172) Closing Cash Balance 431 404 483 1,126 Free Cash Flow 404 483 1,126 1,899 Key Ratios Y/E March FY16 FY17 FY18E FY19E Profitability (%) EBITDA Margin 52.0 54.4 58.5 59.3 APAT Margin 74.1 58.8 57.1 56.8 RoE 20.3 16.9 18.5 19.1 RoIC or Core RoCE 64.5 101.2 128.0 139.1 RoCE 7.9 11.1 13.2 13.8 Eiciency Tax Rate (%) 40.9 25.7 27.0 27.5 Fixed Asset Turnover (x) 21.2 14.5 11.8 10.3 Payables (days) 45 49 45 45 Cash Conversion Cycle (days) (7) (16) (10) (7) Net Debt/EBITDA (x) (7.8) (6.9) (5.7) (5.4) Net Debt/Equity (x) (1.0) (1.0) (1.0) (1.0) Interest Coverage (x) N.A. N.A. N.A. N.A. Per Share Data (Rs) EPS 8.7 8.2 10.0 11.7 CEPS 9.1 8.6 10.5 12.2 DPS 2.2 2.5 3.0 3.5 BV 45.9 51.0 57.5 64.9 Valuation P/E (x) 42.7 45.2 37.0 31.8 P/BV (x) 8.1 7.3 6.5 5.7 EV/EBITDA (x) 56.2 45.4 32.9 27.2 OCF/EV (%) (0.2) 2.2 3.0 3.6 FCF/EV (%) 1.1 1.3 3.2 5.5 FCFE/mkt cap (%) 1.0 1.2 2.9 4.9 Dividend Yield (%) 0.6 0.7 0.8 0.9 5

Rating Guides Rating Expected absolute returns (%) over 12 months >10% HOLD -5% to 10% REDUCE >-5% Reliance Securities Limited (RSL), the broking arm of Reliance Capital is one of the India s leading retail broking houses. Reliance Capital is amongst India s leading and most valuable financial services companies in the private sector. Reliance Capital has interests in asset management and mutual funds, life and general insurance, commercial finance, equities and commodities broking, wealth management services, distribution of financial products, private equity, asset reconstruction, proprietary investments and other activities in financial services. The list of associates of RSL is available on the website www.reliancecapital.co.in. RSL is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014 General Disclaimers: This Research Report (hereinafter called Report ) is prepared and distributed by RSL for information purposes only. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through RSL nor any solicitation or oering of any investment /trading opportunity on behalf of the issuer(s) of the respective security(ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by RSL to be reliable. RSL or its directors, employees, ailiates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, ailiates or representatives of RSL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. Risks: Trading and investment in securities are subject to market risks. There are no assurances or guarantees that the objectives of any of trading / investment in securities will be achieved. The trades/ investments referred to herein may not be suitable to all categories of traders/investors. The names of securities mentioned herein do not in any manner indicate their prospects or returns. The value of securities referred to herein may be adversely aected by the performance or otherwise of the respective issuer companies, changes in the market conditions, micro and macro factors and forces aecting capital markets like interest rate risk, credit risk, liquidity risk and reinvestment risk. Derivative products may also be aected by various risks including but not limited to counter party risk, market risk, valuation risk, liquidity risk and other risks. Besides the price of the underlying asset, volatility, tenor and interest rates may aect the pricing of derivatives. Disclaimers in respect of jurisdiction: The possession, circulation and/or distribution of this Report may be restricted or regulated in certain jurisdictions by appropriate laws. No action has been or will be taken by RSL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/ or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. RSL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to RSL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India. Disclosure of Interest: The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/ opinions in respect of the securities and their respective issuers. None of RSL, research analysts, or their relatives had any known direct /indirect material conflict of interest including any long/short position(s) in any specific security on which views/opinions have been made in this Report, during its preparation. RSL s Associates may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report. RSL, its Associates, the research analysts, or their relatives might have financial interest in the issuer company(ies) of the said securities. RSL or its Associates may have received a compensation from the said issuer company(ies) in last 12 months for the brokerage or non brokerage services.rsl, its Associates, the research analysts or their relatives have not received any compensation or other benefits directly or indirectly from the said issuer company(ies) or any third party in last 12 months in any respect whatsoever for preparation of this report. The research analysts has served as an oicer, director or employee of the said issuer company(ies)?: No RSL, its Associates, the research analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies).?: No Copyright: The copyright in this Report belongs exclusively to RSL. This Report shall only be read by those persons to whom it has been delivered. No reprinting, reproduction, copying, distribution of this Report in any manner whatsoever, in whole or in part, is permitted without the prior express written consent of RSL. RSL s activities were neither suspended nor have defaulted with any stock exchange with whom RSL is registered. Further, there does not exist any material adverse order/judgments/ strictures assessed by any regulatory, government or public authority or agency or any law enforcing agency in last three years. Further, there does not exist any material enquiry of whatsoever nature instituted or pending against RSL as on the date of this Report. Important These disclaimers, risks and other disclosures must be read in conjunction with the information / opinions / views of which they form part of. RSL CIN: U65990MH2005PLC154052. SEBI registration no. ( Stock Brokers: NSE - INB / INF / INE 231234833; BSE - INB / INF / INE 011234839, Depository Participants: -DP-257-2016 IN-DP-NSDL-363-2013, Research Analyst: INH000002384); AMFI ARN No.29889. 6